TG Therapeutics saw a positive improvement to its Relative Strength (RS) Rating on Thursday, rising from 87 to 91.
How To Use Stock Charts To Stay Profitable And Protected
IBD's proprietary rating identifies share price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the last 52 weeks holds up against all the other stocks in our database.
History shows that the top-performing stocks typically have an RS Rating north of 80 at the beginning of a new run.
TG Therapeutics is trying to complete a consolidation with a 46.48 buy point. See if it can break out in heavy trade. Be aware that it's a third-stage base. Such later-stage patterns involve more risk and are more and have a higher likelihood to fail than first- or second-stage consolidations.
The company showed 0% EPS growth in its most recent report, while sales growth came in at 90%. The next quarterly results are expected on or around Aug. 5.
TG Therapeutics holds the No. 2 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
